Skip to main content

Breast Cancer

Breast Cancer

Palbociclib in Combination with Aromatase Inhibitors in Elderly Patients with Estrogen Receptor–Positive and HER2-Negative Advanced Breast Cancer

Breast Cancer

Olaparib as Adjuvant Therapy in Patients with BRCA1 or BRCA2 Mutation–Positive Breast Cancer

Breast Cancer

Olaparib’s OlympiA Trial Crossed the Superiority Limit for Invasive Disease-Free Survival versus Placebo

Breast Cancer

Real-World Tumor Response of Palbociclib plus Letrozole versus Letrozole for Metastatic Breast Cancer in US Clinical Practice

Breast Cancer

Olaparib Monotherapy in Germline BRCA Mutation–Positive, HER2-Negative Metastatic Breast Cancer in the Real-World Setting

Breast Cancer, CDK4/6 Inhibitors

CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status: A Real-World Evidence Study

Breast Cancer, PARP Inhibitors

A Summary of PARP Inhibitors for the Treatment of Breast Cancer

Breast Cancer, CDK4/6 Inhibitors

Overall Survival in Patients with HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer Treated with a CDK4/6 Inhibitor plus Fulvestrant: An FDA Pooled Analysis

Breast Cancer

Real-World Patient-Reported Outcomes, Clinical Profile, and Treatment Patterns in a Subset of Patients with HR-Positive, HER2-Negative, Advanced Breast Cancer with Poor Prognostic Factors

Breast Cancer

A Web-Based Survey on Suggested Modifications in the Management of Patients with Breast Cancer During the COVID-19 Pandemic

2
3
4
5
6
7
8

Page 5 of 12
Results 41 - 50 of 114